MEPSGEN announced the launch of NanoCalibur Mini on October 26, 2026, adding an automated small-volume nanoparticle formulation system for early-stage drug research and development.

Key Takeaways

  • The system formulates lipid and polymeric nanoparticles in volumes of 0.1–3 mL.
  • Mini joins the Lab, Pro and GMP systems in MEPSGEN’s NanoCalibur lineup.

What NanoCalibur Mini does

The system uses microfluidic technology to formulate nanoparticles, which can carry therapeutic payloads in applications such as mRNA and gene therapies. Researchers can select one of two single-use cartridges, covering volumes of 0.1–0.4 mL or 0.4–3 mL.

MEPSGEN says the system is intended for testing formulation conditions with limited material, from early screening through a range of preclinical studies.

How the system fits the product lineup

Mini completes a four-system series that also includes Lab, Pro and GMP. MEPSGEN says the systems use the same microfluidic mixing pattern, structure and dimensions, increasing throughput by running identical mixing units in parallel.

The design is intended to reduce the need to re-optimize processes as production scales up and technology is transferred. The company also says it is engineered to maintain stable shear conditions as production grows.

Launch offers and availability

MEPSGEN announced the launch but did not specify pricing or geographic availability. It plans promotional offers through the end of 2026 for research institutions and pharmaceutical and biotechnology companies evaluating the system, with details to be announced.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.